KR20250163416A - 플라즈미노겐 활성인자 억제제 1 (pai-1) 억제제 및 이의 용도 - Google Patents
플라즈미노겐 활성인자 억제제 1 (pai-1) 억제제 및 이의 용도Info
- Publication number
- KR20250163416A KR20250163416A KR1020257037244A KR20257037244A KR20250163416A KR 20250163416 A KR20250163416 A KR 20250163416A KR 1020257037244 A KR1020257037244 A KR 1020257037244A KR 20257037244 A KR20257037244 A KR 20257037244A KR 20250163416 A KR20250163416 A KR 20250163416A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- pai
- inhibitor
- administration
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dispersion Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Biophysics (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731074P | 2018-09-13 | 2018-09-13 | |
| US62/731,074 | 2018-09-13 | ||
| KR1020217010851A KR102884331B1 (ko) | 2018-09-13 | 2019-09-12 | 플라즈미노겐 활성인자 억제제 1 (pai-1) 억제제 및 이의 용도 |
| PCT/US2019/050849 WO2020056160A1 (en) | 2018-09-13 | 2019-09-12 | Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217010851A Division KR102884331B1 (ko) | 2018-09-13 | 2019-09-12 | 플라즈미노겐 활성인자 억제제 1 (pai-1) 억제제 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250163416A true KR20250163416A (ko) | 2025-11-20 |
Family
ID=68052024
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257037244A Pending KR20250163416A (ko) | 2018-09-13 | 2019-09-12 | 플라즈미노겐 활성인자 억제제 1 (pai-1) 억제제 및 이의 용도 |
| KR1020217010851A Active KR102884331B1 (ko) | 2018-09-13 | 2019-09-12 | 플라즈미노겐 활성인자 억제제 1 (pai-1) 억제제 및 이의 용도 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217010851A Active KR102884331B1 (ko) | 2018-09-13 | 2019-09-12 | 플라즈미노겐 활성인자 억제제 1 (pai-1) 억제제 및 이의 용도 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220105068A1 (https=) |
| EP (1) | EP3849539A1 (https=) |
| JP (2) | JP2021535925A (https=) |
| KR (2) | KR20250163416A (https=) |
| CN (2) | CN113056268A (https=) |
| AU (1) | AU2019338459B2 (https=) |
| BR (1) | BR112021004542A2 (https=) |
| CA (1) | CA3112558A1 (https=) |
| IL (1) | IL281450A (https=) |
| MX (2) | MX2021002995A (https=) |
| SG (1) | SG11202102478SA (https=) |
| WO (1) | WO2020056160A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019005833A (es) | 2016-11-21 | 2019-10-30 | Eirion Therapeutics Inc | Administracion transdermica de agentes grandes. |
| CN113155987B (zh) * | 2020-12-28 | 2023-06-06 | 浙江工商大学 | 一种微针贴片及其制备方法、应用 |
| AU2024344613A1 (en) | 2023-09-18 | 2026-04-23 | Eirion Therapeutics, Inc. | Topical compositions and uses of pai-1 inhibitors |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US296006A (en) | 1884-04-01 | John hoefleb | ||
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1261849B (it) | 1993-09-02 | 1996-06-03 | Avantgarde Spa | Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici. |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| US5965154A (en) | 1998-03-17 | 1999-10-12 | Plc Holding, L.L.C. | Adhesive matrix type transdermal patch and method of manufacturing same |
| US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
| US6611707B1 (en) | 1999-06-04 | 2003-08-26 | Georgia Tech Research Corporation | Microneedle drug delivery device |
| AU2001229441A1 (en) * | 2000-01-14 | 2001-07-24 | Tanox, Inc. | Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease |
| US6908453B2 (en) | 2002-01-15 | 2005-06-21 | 3M Innovative Properties Company | Microneedle devices and methods of manufacture |
| WO2003071267A1 (en) * | 2002-02-19 | 2003-08-28 | Vanderbilt University | Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors |
| JP2006507297A (ja) * | 2002-05-13 | 2006-03-02 | チルドレンズ・ホスピタル・ロサンジェルス | ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防 |
| AU2005274574B2 (en) * | 2004-08-18 | 2011-03-17 | Ace Aps | Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists |
| KR102110379B1 (ko) | 2005-12-01 | 2020-05-14 | 유니버시티 오브 메사츄세츠 로웰 | 보툴리눔 나노에멀젼 |
| US8658391B2 (en) | 2006-04-27 | 2014-02-25 | Anterios, Inc. | Assessment of the effects of topical administration of chemodenervating pharmaceuticals |
| SG177184A1 (en) | 2006-12-01 | 2012-01-30 | Anterios Inc | Amphiphilic entity nanoparticles |
| EP2272822A4 (en) * | 2008-03-31 | 2012-01-18 | Renascience Co Ltd | PLASMINOG ACTIVATOR-1 HEMMER |
| KR101848095B1 (ko) | 2008-06-26 | 2018-04-11 | 안테리오스, 인코퍼레이티드 | 경피 운반 |
| WO2010148572A1 (en) * | 2009-06-26 | 2010-12-29 | Asan Laboratories Co., Ltd. | Method for treating or ameliorating mucocutaneous or ocular toxicities |
| US20120328701A1 (en) | 2011-01-24 | 2012-12-27 | Anterios, Inc. | Nanoparticle compositions, formulations thereof, and uses therefor |
| BR112013018918A2 (pt) | 2011-01-24 | 2016-10-04 | Anterios Inc | composições de nanopartículas |
| US9144671B2 (en) | 2011-12-21 | 2015-09-29 | 3M Innovative Properties Company | Transdermal adhesive patch assembly with removable microneedle array and method of using same |
-
2019
- 2019-09-12 KR KR1020257037244A patent/KR20250163416A/ko active Pending
- 2019-09-12 AU AU2019338459A patent/AU2019338459B2/en active Active
- 2019-09-12 JP JP2021514401A patent/JP2021535925A/ja active Pending
- 2019-09-12 CN CN201980074633.8A patent/CN113056268A/zh active Pending
- 2019-09-12 KR KR1020217010851A patent/KR102884331B1/ko active Active
- 2019-09-12 WO PCT/US2019/050849 patent/WO2020056160A1/en not_active Ceased
- 2019-09-12 MX MX2021002995A patent/MX2021002995A/es unknown
- 2019-09-12 CA CA3112558A patent/CA3112558A1/en active Pending
- 2019-09-12 US US17/274,948 patent/US20220105068A1/en active Pending
- 2019-09-12 EP EP19773718.2A patent/EP3849539A1/en active Pending
- 2019-09-12 SG SG11202102478SA patent/SG11202102478SA/en unknown
- 2019-09-12 BR BR112021004542-2A patent/BR112021004542A2/pt unknown
- 2019-09-12 CN CN202511057022.6A patent/CN120983628A/zh active Pending
-
2021
- 2021-03-11 IL IL281450A patent/IL281450A/en unknown
- 2021-03-12 MX MX2025004193A patent/MX2025004193A/es unknown
-
2024
- 2024-09-12 JP JP2024158484A patent/JP2025011085A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021002995A (es) | 2021-07-15 |
| US20220105068A1 (en) | 2022-04-07 |
| KR102884331B1 (ko) | 2025-11-13 |
| MX2025004193A (es) | 2025-05-02 |
| CN113056268A (zh) | 2021-06-29 |
| EP3849539A1 (en) | 2021-07-21 |
| IL281450A (en) | 2021-04-29 |
| WO2020056160A1 (en) | 2020-03-19 |
| BR112021004542A2 (pt) | 2021-06-08 |
| AU2019338459A1 (en) | 2021-04-08 |
| JP2021535925A (ja) | 2021-12-23 |
| CA3112558A1 (en) | 2020-03-19 |
| AU2019338459B2 (en) | 2025-07-10 |
| CN120983628A (zh) | 2025-11-21 |
| SG11202102478SA (en) | 2021-04-29 |
| JP2025011085A (ja) | 2025-01-23 |
| KR20210057141A (ko) | 2021-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018347514C1 (en) | Methods and compositions for topical delivery | |
| KR101848095B1 (ko) | 경피 운반 | |
| JP6131194B2 (ja) | 皮膚科学的症状を処置するためのエンプティナノ粒子組成物およびその使用 | |
| JP2025011085A (ja) | プラスミノーゲンアクチベーターインヒビター１（ｐｌａｓｍｉｎｏｇｅｎ ａｃｔｉｖａｔｏｒ ｉｎｈｉｂｉｔｏｒ １）（ＰＡＩ－１）阻害剤（ｉｎｈｉｂｉｔｏｒ）およびその使用 | |
| JP2014503587A (ja) | 界面活性剤組成物 | |
| JP2025138639A (ja) | プラスミノーゲンアクチベーターインヒビター１（ｐｌａｓｍｉｎｏｇｅｎ ａｃｔｉｖａｔｏｒ ｉｎｈｉｂｉｔｏｒ １）（ＰＡＩ－１）阻害剤（ｉｎｈｉｂｉｔｏｒ）の使用 | |
| HK40055571A (en) | Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor | |
| HK40055572A (en) | Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors | |
| AU2024344613A1 (en) | Topical compositions and uses of pai-1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |